GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Repair Ltd (ASX:TRP) » Definitions » Other Current Receivables

Tissue Repair (ASX:TRP) Other Current Receivables : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tissue Repair Other Current Receivables?

Tissue Repair's Other Current Receivables for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Tissue Repair's annual Other Current Receivables increased from Jun. 2022 (A$0.05 Mil) to Jun. 2023 (A$0.83 Mil) and increased from Jun. 2023 (A$0.83 Mil) to Jun. 2024 (A$2.53 Mil).


Tissue Repair Other Current Receivables Historical Data

The historical data trend for Tissue Repair's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Repair Other Current Receivables Chart

Tissue Repair Annual Data
Trend Jun22 Jun23 Jun24
Other Current Receivables
0.05 0.83 2.53

Tissue Repair Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Current Receivables Get a 7-Day Free Trial - 0.83 - 2.53 -

Tissue Repair Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.


Tissue Repair Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Tissue Repair's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Tissue Repair Business Description

Traded in Other Exchanges
N/A
Address
255 Pitt Street, Level 10, Sydney, NSW, AUS, 2000
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.